| 摘要 |
<p>A vaccine against feline leukaemia virus (FeLV) comprises a protein formed of two proteins derived from FeLV gp70 which are not adjacent in the native protein, particularly VR1 and VR5 or effective fragments thereof. VR5 is preferably attached to the carboxy terminus of VR1. A co-protein such as GST or β-galactosidase may be attached to the amino terminus of the fused protein, such as to stabilise and solubilise the fused protein. Attachments to the carboxy terminus may reduce the immunogenicity.</p> |
